Macquarie Group
KRYS icon

Macquarie Group’s Krystal Biotech KRYS Stock Holding History

Macquarie Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-382
Closed -$44K – 1951
2022
Q3 		$44K Sell
382
-246
-39% -$17.8K ﹤0.01% 1989
2022
Q2 		$41K Hold
628
– – ﹤0.01% 2102
2022
Q1 		$42 Hold
628
– – ﹤0.01% 2199
2021
Q4 		$44K Hold
628
– – ﹤0.01% 2197
2021
Q3 		$33K Hold
628
– – ﹤0.01% 2338
2021
Q2 		$43K Hold
628
– – ﹤0.01% 2189
2021
Q1 		$48K Sell
628
-116
-16% -$8.43K ﹤0.01% 2086
2020
Q4 		$45K Hold
744
– – ﹤0.01% 2064
2020
Q3 		$32K Hold
744
– – ﹤0.01% 2051
2020
Q2 		$31K Buy
+744
New +$35.8K ﹤0.01% 2046

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Macquarie Group's KRYS Position: Q4 2022 in Review

Macquarie Group sold out of Krystal Biotech (KRYS) in Q4 2022, closing a stake of 382 shares — an estimated $44K sold.

Macquarie Group first reported a position in KRYS in Q2 2020 and held it in 10 quarters. The position peaked at $48K in Q1 2021. 154 funds tracked by Wall St. Rank hold KRYS as of Q4 2022.

  • Macquarie Group reported no remaining Krystal Biotech position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 382 Krystal Biotech shares in Q4 2022, an estimated $44K.
  • Macquarie Group first reported a position in Krystal Biotech in Q2 2020 and held it in 10 quarters.
  • Macquarie Group's Krystal Biotech position peaked at $48K in Q1 2021.
  • 154 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.